Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Immunization with the DNA-Encoding N-Terminal Domain of Proteophosphoglycan of Leishmania donovani Generates Th1-Type Immunoprotective Response against Experimental Visceral Leishmaniasis

Mukesh Samant, Reema Gupta, Shraddha Kumari, Pragya Misra, Prashant Khare, Pramod Kumar Kushawaha, Amogh Anant Sahasrabuddhe and Anuradha Dube
J Immunol July 1, 2009, 183 (1) 470-479; DOI: https://doi.org/10.4049/jimmunol.0900265
Mukesh Samant
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reema Gupta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shraddha Kumari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pragya Misra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prashant Khare
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pramod Kumar Kushawaha
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amogh Anant Sahasrabuddhe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anuradha Dube
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Leishmania produce several types of mucin-like glycoproteins called proteophosphoglycans (PPGs) which exist as secretory as well as surface-bound forms in both promastigotes and amastigotes. The structure and function of PPGs have been reported to be species and stage specific as in the case of Leishmania major and Leishmania mexicana; there has been no such information available for Leishmania donovani. We have recently demonstrated that PPG is differentially expressed in sodium stibogluconate-sensitive and -resistant clinical isolates of L. donovani. To further elucidate the structure and function of the ppg gene of L. donovani, a partial sequence of its N-terminal domain of 1.6 kb containing the majority of antigenic determinants, was successfully cloned and expressed in prokaryotic as well as mammalian cells. We further evaluated the DNA-encoding N-terminal domain of the ppg gene as a vaccine in golden hamsters (Mesocricetus auratus) against the L. donovani challenge. The prophylactic efficacy to the tune of ∼80% was observed in vaccinated hamsters and all of them could survive beyond 6 mo after challenge. The efficacy was supported by a surge in inducible NO synthase, IFN-γ, TNF-α, and IL-12 mRNA levels along with extreme down-regulation of TGF-β, IL-4, and IL-10. A rise in the level of Leishmania-specific IgG2 was also observed which was indicative of enhanced cellular immune response. The results suggest the N-terminal domain of L. donovani ppg as a potential DNA vaccine against visceral leishmaniasis.

Leishmania produce a range of glycoconjugates containing phosphoglycan (PG)3 that includes membrane-bound lipophosphoglycan and proteophosphoglycans (PPG), as well as secreted PG and acid phosphatase (1). These glycoconjugates have been shown to play important roles in parasite virulence both in vector and the mammalian host (2, 3, 4, 5, 6). Among these PPGs are newly described mucin-like glycoproteins present on the surface and secreted by both promastigote and amastigote stages of Leishmania. These proteins are thought to be important in the transmission, invasion, and subsequent intracellular survival of parasites (7). The structure and function of PPGs are species and stage specific as in the case of Leishmania major and Leishmania mexicana, but no such information has hitherto been available for Leishmania donovani (8, 9, 10, 11). We have very recently demonstrated the expression of PPG to be higher in sodium stibogluconate-resistant clinical isolates of L. donovani as compared with the sensitive ones (11).

It was proposed earlier that the assembly of PGs in the parasites may provide targets for the rational development of new Leishmania-specific drugs/vaccines (12). Considerable efforts were made to elucidate the biosynthetic pathway of the lipid-linked PGs in lipophosphoglycans (2, 13, 14, 15, 16). Much less is known about the biosynthesis of the PPGs since a prerequisite for such studies is sequence information about their protein backbones. To date, the genes encoding PPG from L. major and L. mexicana have only been cloned. Ilg et al. (17) identified the ppg1 gene of L. major promastigotes encoding a membrane-bound PPG consisting of a large central domain of ∼100 repeats of the sequence APSASSSSA(P/S)SSSSS(9/S). The N-terminal to the central repetitive domain is a nonrepetitive sequence containing a leucine-rich repeat motif (17, 18) and the carboxyl terminus consists of a second nonrepetitive region terminating in a hydrophobic amino acid sequence compatible with GPI addition (9, 17). This gene is distinct from the single copy ppg2 gene of L. mexicana that contains a different serine-rich repetitive sequence (9) and encodes a secreted nonfilamentous PPG that is expressed by both promastigotes and amastigotes. The sequence of another ppg gene, i.e., ppg3 in L. major, revealed that this 4.3-kb long gene (19), containing N-terminal domain and central serine-rich repetitive sequence, is different from ppg1 and ppg2 genes of L. major and L. mexicana, respectively, and comparatively more simpler in amino acid composition. Moreover, it has extracellular localization and showed its homology to other surface Ag proteins as observed by Blastp/TblastN/BlastX analysis. In the present communication, the characterization of the ppg gene of L. donovani was initiated with the N-terminal domain since it contains the majority of antigenic determinants (20) (Fig. 1⇓).

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

The schematic structure of PPG (11 75 ) (A) and Ag determinants in ppg using Ag determination software (B).

Active visceral leishmaniasis (VL) is associated with the absence of parasite-specific cell-mediated immune response (21, 22). It has been suggested that disease susceptibility in VL is due to the lack of Th1 response rather than the presence of Th2 response (23). In the clinical model Leishmania, Ag-specific expansion of both Th1 and Th2 subsets capable of producing IFN-γ as well as IL-4 and IL-10 are found in cured VL patients (24, 25). Since the current scenario for control measures rely only on chemotherapy and the available chemotherapeutic agents being inadequate, expensive, and often toxic (26, 27), an alternative choice is immunoprophylaxis. Keeping this in view, we further formulated an effective DNA-encoding N-terminal domain of the ppg gene and evaluated it as a vaccine candidate against challenge of L. donovani in golden hamsters, a good model for VL as it develops a progressive, lethal disease which very closely mimics the disease in humans and as such has been used for vaccination studies (28, 29). The studies were therefore performed to assess whether the resultant protective ability of genetically immunized hamsters was due to a polarized Th1-like response, or to a mixed Th1/Th2-like response, representative of a clinically cured VL scenario. Our studies indicate a strong protective response in VL depending on T cell functionality-Th1-type cytokine response detected for the first time through real-time quantitative RT-PCR and induction of leishmanicidal effector molecules.

Materials and Methods

Cell culture

Baby hamster kidney cell line BHK-21was procured from the National Centre for Cell Science (Pune, India). Cells were grown in RPMI 1640 (Invitrogen Life Technologies) supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 4 mM NaHCO3, 20 mM HEPES, along with 10% FCS (Life Technologies at 37°C in the presence of a 5% CO2 supply.

Animals

Laboratory inbred male golden hamsters (Mesocricetus auratus, 45–50 g) from the Institute’s animal house facility were used for experimental purposes with prior approval of the animal ethics committee of the Central Drug Research Institute (Lucknow, India). They were housed in climatically controlled rooms and fed with standard rodent food pellet (Lipton India) and water ad libitum.

Parasites

The L. donovani strains sodium stibogluconate-resistant 2039 (procured from a patient admitted to the Kala Azar Medical Research Centre, Muzzafarpur, Bihar) and WHO reference strain Dd8 were cultured in vitro as described elsewhere (30). The strains have also been maintained in hamsters through serial passage, i.e., from amastigote to amastigote. For bulk cultivation, promastigotes were grown in L-15 medium (Sigma-Aldrich) with l-glutamine, supplemented with 10% tryptose phosphate broth (Himedia), 0.1% gentamicin, and 10% FBS (Life Technologies). Parasites were harvested after 3–4 days of culture (31).

Cloning and expression of N-terminal domain of ppg (1.6 kb)

L. donovani strain 2039 genomic DNA was isolated from 108 promastigotes, washed, and suspended in NET buffer (10 mM Tris-HCl (pH 7.5), 100 mM NaCl, and 1 mM EDTA) and incubated with proteinase K (1 mg/ml; Invitrogen Life Technologies) and 0.5% SDS at 50°C for 4 h. Nucleic acids were extracted by phenol:chloroform:isoamyl alcohol extraction and ethanol precipitation. Genomic DNA was spooled and subjected to RNase (100 μg/ml) treatment. N-terminal domain of the ppg gene was amplified using Taq Polymerase (Sigma-Aldrich) lacking a 3′–5′ exonuclease activity. PCR was performed using ppg-specific primers (based on the L. major ppg3 gene sequence): forward, 5′-GGATCCACCATGTCTTTTCATAGGCGCCGG-3′ and reverse, 5′-GGATCCATCTGGAATTGTGAGGTGCACCAATCG-3′(BamHI site underlined) in a Thermocycler (Bio-Rad) under conditions at one cycle of 94°C for 4 min, 30 cycles of 94°C for 45 s, 60°C for 45 s, and 72°C for 1 min 30 s, and finally one cycle of 72°C for 10 min. Amplified PCR product was electrophoresed in agarose gel and eluted from the gel by GenElute Columns (Qiagen). Eluted product was cloned in pTZ57R/T (T/A) cloning vector (Fermentas) and transformed into competent DH5α cells. The transformants were screened for the presence of recombinant plasmids with the ppg insert by gene-specific PCR under similar conditions as previously mentioned. Isolated positive clones were sequenced from Delhi University (New Delhi) and submitted to the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/nuccore/119656394; accession no. EF141073). ppg was further subcloned at the BamHI site in bacterial pET28a (Novagen) and mammalian expression pcDNA3 (Invitrogen) vectors.

The expression of PPG was checked in bacterial cells by transforming the ppg+pET28a construct in Escherichia coli Rosetta strain. The transformed cells were inoculated into 5-ml test tube culture medium (Luria-Bertani) and allowed to grow at 37°C in a shaker at 220 rpm. Cultures in logarithmic phase (at OD600 of ∼0.5–0.6) were induced for 3 h with 1.0 mM isopropyl-β-d-thiogalactopyranoside (IPTG) at 37°C. After induction, cells were lysed in 5× sample buffer (0.313 M Tris-HCl (pH 6.8), 50% glycerol, 10% SDS, and 0.05% bromphenol blue, with 100 mM DTT) and whole cell lysates (WCL) were analyzed by 12% SDS-PAGE (32). Uninduced control culture was analyzed in parallel. The separated proteins from the polyacrylamide gel were transferred onto a nitrocellulose membrane in a semidry blot apparatus (Amersham) as described earlier (33). Membrane was incubated for 1 h in blocking buffer followed by a 2-h incubation at room temperature with mouse anti-His Ab (Novagen) as primary Ab (1/2500 dilution) and then incubated with goat anti-mouse HRP conjugate Ab (1/10,000; Bangalore Genie) for 1 h at room temperature. The blot was developed using an ECL kit (GE Biosciences).

The expression of PPG was further checked in mammalian cells by transfecting the ppg+pcDNA3 construct in BHK cells. For transfection and vaccination studies, endotoxin-free plasmid DNA was isolated using an Endofree plasmid purification Maxi kit as per the manufacturer’s protocol (Qiagen). For confirmation and cellular localization of the proteins expressed by the ppg+pcDNA3 construct, 2 × 105 BHK cells were grown in four-chamber slides and transfected with four different sets of plasmids, the blank pcDNA3 plasmid (as negative control), ppg+pcDNA3 construct, and gfp+pcDNA3 construct (as positive control) and cotransfected with ppg+gfp-containing plasmids in serum-free DMEM (Life Technologies) using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. Expression was confirmed by RT-PCR and fluorescence microscopy. For RT-PCR, RNA was isolated from the transfected BHK cell line using TRIzol (Sigma-Aldrich) and the cDNA was synthesized using Moloney murine leukemia virus- reverse transcriptase as per the manufacturer’s protocol (Fermentas). Resulting cDNA was treated with RNase (10 μg/μl; Fermentas) and used as template to amplify the ppg gene using gene-specific primers. The expression of ppg at the appropriate cellular localizations was also confirmed by immunofluorescence using polyclonal Ab raised in rabbit against deglycosylated and dephosphorylated native filamentous PPG of L. major (gift from Dr. E. Handman, The Walter and Eliza Hall Institute of Medical Sciences, Melbourne, Australia). BHK cells were plated in four-chamber slides and allowed to grow for 24 h. For detection of intracellular PPG, cells were fixed using 4% paraformaldehyde and permeabilized by 0.5% Triton X-100 for 10 min followed by incubation with the same primary anti-serum and secondary anti-rabbit FITC conjugate (Bangalore Genei) for 1 h at room temperature. After washing in PBS, cells were visualized under a fluorescence microscope (Eclipse 80i Nikon). Cells transfected with the gfp+pcDNA3 construct was visualized directly under a fluorescence microscope.

Vaccination with ppg+pcDNA3 construct in hamsters

For immunization, a total of 85 Syrian golden hamsters (40–45 g) were divided into the following four groups, each containing 20–25 animals, wherein groups 1–3 served as controls as described below and group 4 as the main experimental group: group 1, unvaccinated and unchallenged (normal control); group 2, unvaccinated and challenged (infected control); group 3, pcDNA3 vaccinated (vector control); and group 4, ppg+pcDNA3 vaccinated (vaccinated group). The experimental schedules for vaccination/immunization were conducted as described below:

Day 0: vaccination.

Hamsters of group 3 were injected i.m. in the thigh muscle of the hind leg with 100 μg of pcDNA3 (blank vector)/100 μl of PBS, whereas group 4 was injected i.m. with 100 μg of ppg+pcDNA3 construct/100 μl of PBS.

Days 7 and 14 after vaccination.

Two booster doses of 100 μg of ppg+pcDNA3 construct were given i.m. to group 4.

Day 21 after vaccination.

Two hamsters, one each from group 3 and group 4, were sacrificed and their thigh muscles were taken out (at the site of immunization) to detect the in vivo expression of PPG at the DNA level.

On the same day, each animal of groups 2–4 was challenged intracardially with 107 late log-phase promastigotes of the Dd8 strain of L. donovani. On days 0, 45, 60, 120, and 180 postchallenge (p.c.), three to five hamsters per group were necropsied for parasitological and immunological assessment of progression of VL.

Detection of ppg DNA levels in muscles of hamster immunized with ppg+pcDNA3 construct by Southern blotting

For detection of the ppg DNA level in hamsters, total DNA was extracted from the muscle of ppg+pcDNA3- immunized as well as pcDNA3 blank vector-immunized hamsters using a NucleoSpin nucleic acid purification kit (MACHEREY-NAGEL) as per the manufacturer’s protocol. PCR amplification of the ppg gene was conducted using muscle DNA of hamsters as template as described earlier. For probe synthesis, PCR was performed using digoxigenin-labeled dUTPs (Roche) and ppg+pcDNA3 plasmid as template. The amplified product was resolved in 1% agarose gel, transferred onto nylon membranes (Hybond-N+; Amersham Biosciences), and subjected to Southern blot analysis with a ppg-specific probe (34, 35).

Measurement of body, spleen, and liver weight of vaccinated hamsters

The body weight and that of the spleen and liver (on necropsy) of hamsters of all of the experimental groups were assessed at different time intervals, i.e., on days 0, 45, 60, 120, and 180 p.c.

Preparation of soluble L. donovani (SLD) promastigote Ag

SLD promastigote Ag was prepared according to the method described by Scott et al. (36) and modified by Choudhry et al. (37). Briefly, late log-phase promastigotes (109) were harvested from 3- to 4-day cultures, washed four times in cold PBS, resuspended in PBS containing protease inhibitors mixture (Sigma-Aldrich), and sonicated (Soniprep-150) for two periods of 1.5 min each in ice, (separated by an interval of 3 min) at medium amplitude. The sonicated sample was subjected to rapid freeze-thawing four times using liquid nitrogen and left at 4°C for 1 h for complete extraction of soluble Ag. The suspension was centrifuged at 4,000 × g for 20 min at 4°C followed by ultracentrifugation at 40,000 × g for 30 min. After assessing protein contents, the Ag was aliquoted and stored at −70°C.

Measurement of delayed-type hypersensitivity (DTH) in hamsters

DTH was performed by injecting 50 μg/50 μl of SLD in PBS intradermally into one footpad and PBS alone into the other one of each of the vaccinated and unvaccinated controls. The response was evaluated 48 h later by measuring the difference in footpad swelling between the two with and without SLD for each animal (38).

Assessment of parasitic burden in vaccinated hamsters

The prophylactic efficacy of all of the experimental groups was assessed on necropsy at different time intervals, i.e., on days 0, 45, 60, 120, and 180 p.c. The impression smears/touch blots of different organs, namely, spleen liver and bone marrow (femur bone) of experimental animals were made and the criteria for the assessment of parasitic burden was based on the counting of the number of amastigotes/1000 cell nuclei in each organ. The percentage of inhibition (PI) of parasite multiplication was calculated in comparison to the unvaccinated control using the following formula: PI = No. of parasite count from infected control − no. of parasites from the vaccinated group/no. of parasite count from infected control × 100.

Immunological assays

For evaluation of cellular and Ab responses, peritoneal exudate cells, inguinal lymph nodes, and blood were collected from hamsters on necropsy at various time intervals, i.e., day 0, 45, 60, 120, and 180 p.c.

Assessment of lymphoproliferative responses in vaccinated hamsters

Lymph nodes of hamsters were excised aseptically and processed for the isolation of lymphocytes (39). The lymphocytes were suspended to 106/ml and cultured at 105 cells/well in 96-well flat-bottom tissue culture plates (Nunc). One hundred microliters of Con A (10 μg/ml; Sigma-Aldrich) or SLD (10 μg/ml) was added to each well in triplicate. Wells without stimulants served as negative controls. Cultures were incubated at 37°C in a CO2 incubator for 3 days in the case of mitogens and for 5 days in the case of SLD Ags. Eighteen hours before termination of culture, 0.5 μCi of [3H]thymidine (BARC) was added to each well and cells were harvested on glass fiber mats (Whatman) and radioactivity was counted in a liquid scintillation counter. Results were expressed as stimulation index (SI), which was calculated as mean cpm of stimulated culture/mean cpm of unstimulated control. SI values of >2.5 were considered as positive response.

Assessment of level of NO activity in macrophages of vaccinated hamsters

The presence of nitrite (NO2−) content was assessed using Griess reagent in the culture supernatants of naive hamster peritoneal macrophages after the exposure with supernatant of stimulated lymphocyte cultures. Briefly, isolated peritoneal macrophages (30) were suspended in culture medium and plated at 106 cells/well and exposed to the supernatants of the above described 5-day-old Ag-stimulated lymphocyte cultures from all of the study groups. The supernatants (100 μl) collected from macrophage cultures 24 h after incubation were mixed with an equal volume of Griess reagent (Sigma-Aldrich) and left for 10 min at room temperature. The absorbance of the reaction was measured at 540 nm in an ELISA reader (40).

Determination of antileishmanial Ab responses in hamsters

The levels of antileishmanial Abs-IgG and its isotypes, IgG1 and IgG2, in sera samples from hamsters of different groups were measured as described earlier (41). The 96-well ELISA plates (Nunc) were coated with SLD (0.2 μg/100 μl/well) overnight at 4°C and blocked with 1% BSA at room temperature for 1 h. The optimum dilution of sera was standardized at 1/200 for IgG, IgG1, and IgG2 for 2 h at room temperature. HRP-conjugated goat anti-hamster IgG (H + L) (Serotec) and biotin-conjugated mouse anti-Armenian and anti-Syrian hamster IgG1 (for IgG1) (BD Pharmingen) as well as mouse anti-Syrian hamster IgG2 (BD Pharmingen) were added for 1 h at room temperature at 1/800 dilutions. IgG1 and IgG2 plates were further incubated with streptavidin-conjugated peroxidase (Sigma-Aldrich) for 1 h. Finally, the substrate O-phenylenediamine dihydrochloride (Sigma-Aldrich) was added and the plate was read at 492 nm.

Estimation of expression of mRNA cytokines by real-time PCR in vaccinated hamsters

Real-time PCR was performed to assess the expression of mRNAs for various cytokines and inducible NO synthase (iNOS) in splenic cells. Splenic tissues were taken from each of the three individual animals randomly chosen from different groups. Total RNA was isolated using Tri-reagent (Sigma-Aldrich) at different time intervals and quantified by using Gene-quant (Bio-Rad). One microgram of total RNA was used for the synthesis of cDNA using a first-strand cDNA synthesis kit (Fermentas).

For real-time PCR, primers were designed using Beacon Designer software (Bio-Rad) on the basis of cytokines and iNOS mRNA sequences available on PubMed (42) (Table-1⇓). Real-time quantitative PCR was conducted as per the protocol described earlier (43). Briefly, it was carried out with 12.5 μl of SYBR green PCR master mix (Bio-Rad), 1 μg of cDNA, and primers at a final concentration of 300 nM in a final volume of 25 μl. PCR was conducted under the following conditions: initial denaturation at 95°C for 2 min followed by 40 cycles, each consisting of denaturation at 95°C for 30 s, annealing at 55°C for 40 s, and extension at 72°C for 40 s per cycle using the iQ5 multicolor real-time PCR system (Bio-Rad). cDNAs from infected hamsters were used as “comparator samples” for quantification of those corresponding to test samples. All quantifications were normalized to the housekeeping gene HGPRT. A no-template control c-DNA was included to eliminate contaminations or nonspecific reactions. The cycle threshold (CT) value was defined as the number of PCR cycles required for the fluorescence signal to exceed the detection threshold value (background noise). Differences in gene expression were calculated by the comparative CT method (43). This method compares test samples to a comparator sample and uses results obtained with a uniformly expressed control gene (HGPRT) to correct for differences in the amounts of RNA present in the two samples being compared to generate a ΔCT value. Results are expressed as the degrees of difference between ΔCT values of test and comparator samples.

View this table:
  • View inline
  • View popup
Table I.

Sequence of forward and reverse primers used for quantitative real-time RT-PCR

Postchallenge survival

Survival of hamsters belonging to group 4 was checked until day 180 p.c. in comparison to the normal hamsters (group 1). Animals in all of the groups were given proper care and were observed for their physical conditions until their survival period. Survivals of individual hamsters were recorded and mean survival period was calculated.

Statistical analysis

Results are expressed as mean ± SD of three to five individual animals per group at designated time points. Three replicates were done. The results (pooled data of three experiments) were analyzed by one-way ANOVA followed by Dunnet’s or Tukey’s post test where appropriate. All of the analyses were done using GraphPad Prism (version 3.03) software.

Results

PPG was cloned, sequenced, and expressed in vitro in E. coli Rosetta strain and in BHK cells as well as in vivo in hamsters

The ppg gene of L. donovani was successfully cloned and sequenced in the T/A cloning vector, which was 95% homologous with L. major ppg3. It was further cloned in right orientation under the T7 promoter in bacterial expression pET28a (Fig. 2⇓I) as well as mammalian expression vector pcDNA3 (Fig. 2⇓III, A). The expression status of the cloned gene when checked in vitro at the protein level in the E. coli Rosetta strain by Western blotting using anti-His Ab exhibited the predicted ∼65.120-kDa recombinant protein (Fig. 2⇓II, B). In BHK cells, the expression level was established at the RNA level by RT-PCR depicting a 1.6-kb band in ppg+gfp cotransfected and ppg transfected but not in vector as well as gfp-transfected cells (Fig. 2⇓III, B). The expression at the protein level was confirmed by fluorescence microscopy using Ab raised in rabbits against deglycosylated and dephosphorylated native filamentous PPG of L. major. The BHK cells transfected with gfp+pcDNA3, ppg+pcDNA3, as well as gfp- and ppg- containing plasmids exhibited bright green fluorescence, indicating the expression of PPG inside the cells. Blank vector-transfected BHK cells showed no fluorescence (Fig. 2⇓IV).

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Cloning and expression of ppg. Clone confirmation of ppg in pET28a vector. M, 1-kb molecular mass marker; lane 1, BamHI-digested ppg+pET28a plasmid construct; lane 2, XhoI-digested plasmid; lane 3, undigested plasmid (I). Expression of rPPG in prokaryotic cells, WCL of transformed E. coli separated on 12% acrylamide gel and stained with Coomassie blue. II, A, Western blot analysis using anti-His mAb. M, Molecular mass markers; Lane 1, WCL before IPTG induction; lane 2, WCL after IPTG (1.0 mM) induction at 37°C (II, B). Clone confirmation of ppg in mammalian expression pcDNA3 vector. M, Molecular mass marker; lane 1, BamHI-digested ppg+ pCDNA3 plasmid construct; lane 2, NotI-digested plasmid; lane 3, XhoI-digested plasmid; lane 4, undigested plasmid (III, A). In vitro expression of ppg in mammalian BHK cell line by RT-PCR (III, B) and fluorescence microscopy (IV). Lanes 1–4 (IIIA) and A–D (IV) are pcDNA3 transfected; gfp+ pcDNA3 transfected; and ppg+pcDNA3 transfected and ppg+gfp cotransfected BHK cells, respectively. In vivo expression of ppg in the hamster, PCR amplification of genomic DNA isolated from muscle tissue of hamsters 3 wk after immunization with pcDNA3 and ppg+pcDNA3 plasmid using ppg-specific primers. M, 1-kb molecular mass marker. Lane 1, pcDNA3; lane 2, ppg+pcDNA3 (V, A). Southern blot analysis of PCR-amplified ppg from the genomic DNA isolated from the muscle tissue of the hamster using the ppg probe (V, B).

The expression level of PPG was also confirmed in vivo at the DNA level by PCR and Southern blotting from immunized hamster tissues. The ppg signal was clearly visible in tissue from hamsters injected with ppg+pcDNA3 construct but not in those hamsters injected with blank vector (Fig. 2⇑V, A). To show the sensitivity and specificity of PCR, the PCR products were detected by Southern blot hybridization using ppg sequence-specific probe. As shown in Fig. 2⇑V, B, hamsters immunized with the ppg+pcDNA3 construct showed a significant amount of ppg DNA in muscle tissue.

Vaccination with ppg DNA-induced optimum protection against L. donovani challenges

The ppg DNA-vaccinated hamsters were found to be protected from the challenge infection of L. donovani, as indicated by their weight gain with time like normal animals. In contrast, there was significant weight loss (p < 0.001) in any of the animals of the infected and vector control groups (Fig. 3⇓A). There was an absence of hepatosplenomegaly in the vaccinated group that is normally associated with the challenge infection (Fig. 3⇓, B and C). A positive correlation of parasite loads with splenomegaly and hepatomegaly was observed among the experimental and control groups. An increase from ∼103 to >104 parasites in all of the groups, except in the ppg DNA-vaccinated group, was seen in Giemsa-stained splenic smears from days 45 to 120 p.c. (Fig. 3⇓D). In the vaccinated group, parasite loads decreased from ∼2 × 102 on day 45 to a negligible level (<10 subsequently) (p < 0.001) by day 180 p.c., rendering them difficult to discern by microscopy (data not shown). Similarly, in liver and bone marrow, parasite loads decreased sharply after day 45 p.c. and parasites were essentially absent by day 180 p.c. in the same vaccinated group (Fig. 3⇓, E and F). Cultivation of the spleen, liver, and lymph node tissues from the vaccinated hamsters in vitro yielded no promastigotes after prolonged incubation for 3 wk.

FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

Body weight (A), spleen weight (B), and liver weight (C) in g as well as parasite burden (no. of amastigotes per 1000 cell nuclei) in the spleen (D), liver (E), and bone marrow (F) on days 0, 45, 90, 120, and 180 p.c. Significance values indicate the difference between the vaccinated groups and infected group (∗, p < 0.05; ∗∗, p < 0.01; and ∗∗∗, p < 0.001).

The ppg DNA-vaccinated hamsters survived the challenges of L. donovani and remained healthy until the day of termination of the experiment, i.e., 6 mo p.c. In contrast, hamsters vaccinated with the pcDNA3 vector and infected control survived for only 2–3 mo.

ppg vaccination stimulates DTH, mitogenic, and Leishmania-specific cellular responses

ppg DNA and blank vector immunizations elicited different cell-mediated immunity (CMI), as determined by assessing the DTH and lymphoblast proliferation responses to specific and/or nonspecific Ags in these hamsters after L. donovani challenges at different time periods. ppg DNA-vaccinated hamsters displayed significant DTH responses, which increased progressively throughout the entire p. c. period (Fig. 4⇓A) and reached the levels that were significantly higher than those of the control groups (p < 0.001) at all time points for the duration of the experiments for up to 180 days.

FIGURE 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4.

DTH response (mm) (A), LTT response (SI value) to SLD (B) and Con A (C), and Leishmania-specific IgG (D) and its isotypes IgG1 (E) and IgG2 (F) in ppg DNA-vaccinated hamsters in comparison to the unimmunized infected controls, vector-immunized controls, and uninfected normal hamsters on days 0, 45, 60, 120, and 180 p.c. Significance values indicate the difference between the vaccinated groups and infected group (∗, p < 0.05; ∗∗, p < 0.01; and ∗∗∗, p < 0.001).

In vitro stimulation of the lymphocytes with Con A showed comparable proliferative response at high levels in all of the groups when assayed before challenges (Fig. 4⇑B, day 0). Con A-induced lymphoproliferative response remained elevated in ppg-vaccinated animals as much as those of the normal hamsters throughout the entire p.c. period (Fig. 4⇑B, normal and vaccinated bars), but it decreased precipitously with time in all of the other control groups. In SLD-specific restimulation assays, the lymphoproliferative response was negative for all groups on prevaccination day 0 (Fig. 4⇑C) and for the nonvaccinated control groups throughout the p.c. period (normal, infected, and vector). Cells from ppg DNA-vaccinated hamsters produced a significantly higher response (p < 0.001), which reached almost to the maximum on day 45 after vaccination and increased further thereafter (Fig. 4⇑C).

ppg DNA vaccination alters Leishmania-specific IgG and its isotypes

The serum levels of leishmanial Ag-specific IgG and its isotypes (IgG1 and IgG2) from all of the groups were assessed by ELISA. The anti-Leishmania IgG and IgG1 were elevated progressively with time to a high level in all groups, except the ppg DNA vaccinated, in which case they remained essentially the background levels of the nonimmunized and unchallenged normal and blank vector immunized (Fig. 4⇑, D and E). In contrast, ppg DNA-vaccinated animals were the only group (Fig. 3⇑F) that showed a significant elevation by 1- to 2-fold over the others (p < 0.01) in the level of IgG2. As a measure of CMI, the elevation of IgG2 was consistent with the development of effective immune responses.

ppg DNA immunization induces NO production in vaccinated hamsters

Lymphocyte-mediated activation of macrophages to produce NO for leishmanicidal activities was found to differ between control and experimental groups of hamsters. Supernatants from stimulated lymphocytes of hamsters vaccinated with the ppg DNA when incubated with naive macrophages produced significant (p < 0.001) amounts of nitrite (19.5 ± 1.94) which was ∼4-fold more than that of unvaccinated infected controls and ∼2.3-fold more than the vector control group on day 45 p.c. Furthermore, the level of nitrite was increased incredibly on days 60 (21.5 ± 2.63), 120, and 180 p.c. (24.13 ± 3.17). Comparatively, a very low amount of nitrite was produced by unvaccinated (5.4 ± 1.3) and vector (5.827 ± 0.6378) control groups on day 45 p.c. (Fig. 5⇓A). Similarly, LPS (100 μg/ml, used as positive control)-stimulated cells from the vaccinated and normal control groups demonstrated good and significant (p < 0.001) nitrite production until day 180 p.c. while infected control and vaccinated with vector alone groups showed less nitrite production until they survived (Fig. 5⇓B).

FIGURE 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 5.

NO production (μM) to LPS (A) and SLD (B) in the naive macrophages coincubated with supernatants of lymphocytes isolated from ppg DNA-immunized hamsters in comparison to the unimmunized infected controls, vector-immunized controls, and uninfected normal hamsters on days 0 45, 60, 120, and 180 p.c. Significance values indicate the difference between the vaccinated groups and infected group (∗∗, p < 0.01 and ∗∗∗, p < 0.001).

ppg DNA vaccination generates Th1-type cytokine profile as determined by quantitative real-time PCR

Impairment of the CMI response during active VL is reflected by marked T cell anergy-specific to Leishmania Ags (44, 45). Since optimum protective efficacy was observed in ppg DNA-vaccinated hamsters, the expression of Th1 and Th2 mRNA cytokines was further evaluated by real-time PCR on days 45 and 60 p.c. The expression of iNOS transcripts was observed to be significantly (p < 0.01 and p < 0.05, respectively, on days 45 and 60) elevated in ppg DNA-immunized hamsters (Fig. 6⇓) at both time points of the study. Similarly, the expression of TNF-α was also significantly higher on day 45 (p < 0.001) and day 60 (p < 0.05) in the vaccinated group (ΔCT = 1.5 ± 0.4 and 2.3 ± 0.3, respectively) in comparison to the L. donovani-infected group (ΔCT = 7.7 ± 0.8 and 5.6 ± 2.5, respectively, on days 45 and 60). The expression of IFN-γ, although variable at different time points, was suppressed in the infected group (ΔCT = 6 ± 0.8, day 45 p.c.), but was significantly higher in the vaccinated group on day 45(p < 0.001) and day 60 (p < 0.05) p.c. and was at par with the normal ones. Similar was the case with IL-12 which was least expressed in the infected group on day 45 p.c. but was significantly (p < 0.01) expressed by 3.5- to 4.0-fold in vaccinated hamsters on days 45 and 60 p.c. On the other hand, the expression of Th2 type cytokines, i.e., TGF-β, IL-4, and IL-10, was significantly up-regulated (p < 0.05 to p < 0.01) in the infected groups compared with the vaccinated hamsters (Fig. 6⇓).

FIGURE 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 6.

Splenic iNOS and cytokine mRNA expression profile analysis of normal, infected, and vaccinated hamsters on days 45 and 60 p.c. by quantitative real-time RT-PCR. Significance values indicate the difference between ΔCT values of infected to normal and vaccinated groups (∗, p < 0.05; ∗∗, p < 0.01; and ∗∗∗, p < 0.001).

Discussion

PPGs exist in both stages of parasites and have the main function in survival and virulence. The elucidation of their primary structure reveals unique proteins, PG structures, and protein carbohydrate linkages which, together with their proposed function(s), provide attractive targets for the development of vaccines and antiparasite drugs (7). To divulge its possible function, it is essential to have knowledge of the genetic makeup of the PPG. We derived the L. donovani ppg gene on the basis of the L. major ppg3 gene sequence with ∼95% homology to L. major. To evolve its function, it was necessary to express ppg in a suitable vector. The PPG was expressed in the E. coli Rosetta strain with pET28a vector and in BHK mammalian cells (at the RNA and protein levels) as well as in hamsters (at the DNA level from immunized hamster muscle tissues) using the pcDNA3 vector. The successful delivery and the expression of the cloned N-terminal domain of PPG in the BHK cell line as well as hamsters further authenticates its evaluation as a DNA vaccine candidate.

In the present study, all of the hamsters immunized with ppg+pcDNA3 and challenged with the virulent Dd8 strain of L. donovani survived the lethal challenge and remained healthy until the termination of the experiment at day 180 p.c., whereas all nonimmunized and blank vector-immunized hamsters succumbed to the lethal L. donovani challenge within 3–4 mo p.c. The advantages with the DNA vaccines include their being protective, stable with low cost of production, no need of cold chain for distribution, and flexibility of combining multiple genes in a simple construct. To date, the most-studied Ags for DNA vaccination against VL were those previously assayed as recombinant proteins (46, 47, 48). Most of them were tested only as single vaccines (48, 49, 50, 51, 52, 53) or as heterologous prime boosts (54) or a vaccinia virus expressing the recombinant protein (55, 56). Protection was observed in vaccines using all of the tested plasmids, particularly pcDNA3 (50, 51, 52, 57) and VR1012 (48).

A major factor of the immune mechanism(s) responsible for protection, which is believed to contribute to healing in visceral leishmaniasis, is the development of strong cell-mediated immunological (CMI) responses like T cell responses, NO production, and DTH responses (42, 53, 58, 59). One measure of CMI is Leishmania-specific lymphocyte transformation test (LTT) related to T cell stimulation with mitogens and Ag in vitro, which almost always accompanies control of parasite growth and healing in humans and animals (28, 60, 61). It appeared that all ppg+pcDNA3-vaccinated hamsters challenged with L. donovani have a specific active T cell response because they displayed significant (p < 0.001) lymphoproliferative responses after challenge that, on the other hand, were severely impeded in nonimmunized infected and healthy control hamsters. However, it is not LTT itself that is behind the primary effector mechanism of immunity, but rather the stimulation of Leishmania-specific T cells to produce macrophage-activating factors, such as NO which helps in activating macrophages to kill the intracellular parasites (62). Here too, the supernatant of SLD-stimulated lymphocytes from ppg-vaccinated hamsters produce a remarkable level of NO in the macrophages of naive hamsters which also support the view regarding the up-regulation of iNOS by Th1 cell-associated cytokines and confirms that the NO-mediated macrophage effector mechanism is critical in the control of parasite replication in the animal model (61). Furthermore, successful vaccination of humans and animals is often related to Ag-induced DTH responses in vivo and T cell stimulation with Ag in vitro (28, 63), suggesting a correlation between cell-mediated immune responses and immunity to infection in this model. Here too, a low level of parasite-specific DTH responses observed in infected and vector control animals can be correlated with disease progression in hamsters which, on the other hand, was strongly expressed in hamsters immunized with DNA vaccine.

Apart from diminished cellular responses, active VL is also associated with the production of high levels of the Leishmania-specific Ab which is observed before detection of parasite-specific T cell response (64). It has been well known that as a measure of CMI, the elevation of IgG2 is consistent with the development of effective immune responses (65). The progressive elevation of the anti-Leishmania IgG and IgG1 in all of the groups except the vaccinated group with time compared with the level of IgG2, which was significantly and consistently prominent in the vaccinated group, suggested that protection against leishmaniasis is induced by a strong T cell response and almost undetectable amounts of Abs (62, 66) which was also seen in clinical as well as experimental VL (31, 50).

The presence of a comparable existence of Th1 and Th2 clones producing both IFN-γ and IL-4 obtained from patients cured of VL encouraged us to assess whether the protective response which was utmost elicited by ppg DNA vaccination in hamsters can reflect this feature of clinical findings (24, 25, 67). The transcript of IFN-γ, a signature cytokine of the Th1-type response that has a dominant effect on macrophage microbicidal responses and other effector killing mechanisms, along with TNF-α, often reported to act in concert to activate iNOS for the production of NO (68, 69), were found to be down-regulated (42) in infected hamsters, whereas their expression was observed to be increased manyfold in the immunized hamsters. IL-10 and IL-4, the key macrophage-deactivating Th1-suppressive cytokines, are reported to have a definitive association with an acute phase of VL during which a progressive increase of IL-10 and IL-4 transcripts in tissues were generated but were not detectable after successful cure (28, 70). Commensurate with these results, an extreme down-regulation of IL-10 and IL-4 mRNA levels was observed in ppg DNA-vaccinated hamsters compared with infected control hamsters (71). Furthermore, the presence of IL-10 as well as IFN-γ was reported in patients with acute VL whereby only IL-10 levels decreased remarkably with disease cure (72). In addition, there are reports that primary Th1 cell-mediated antileishmanial events induced in IL-10-deficient mice require IFN-γ that is largely induced by IL-12 (53, 73). In the present study, IL-12 was completely down-regulated in infected hamster, whereas high levels of IL-12 mRNA transcripts were found in vaccinated hamsters. TGF-β, a pleiotropic cytokine with diverse functions, is known to be expressed at a moderate level even in normal hamsters (28, 42, 53). Unlike the findings of Basu et al. (53) where they could not detect IL-4 transcripts at all in splenocytes of >90% of the infected hamsters, it was quite evident in this study. Furthermore, there was apparent down-regulation of IL-4 expression in all of the immunized hamsters throughout the experiment.

Finally, unlike mice where IL-4 and IL-12 direct IgG subclass switching of IgG1 and IgG2a, respectively, such distinct IgG classes remain obscure in hamsters (38, 74). It is believed that hamster IgG1 and IgG2 correspond to mouse IgG1 and IgG2a/IgG2b, respectively. It has been well established that IgG and IgG1 Abs increase in titer with the L. donovani loads (53). The virtual absence of these Abs is thus consistent with the decreasing parasite loads seen in the vaccinated group. The significant increase in the IgG2 levels only in vaccinated animals is indicative of enhanced CMI.

In a nut shell, this study demonstrated a considerably good prophylactic efficacy of a DNA vaccine encoding ppg against experimental VL since all of the vaccinated hamsters continued to survive beyond 6 mo after challenge. These hamsters were protected by a surge in IFN-γ, TNF-α, and IL-12 levels along with extreme down-regulation of TGF-β, IL-4, and IL-10. The observation was well supported by the rise in the level of Leishmania-specific IgG2 which is indicative of enhanced CMI. These results, therefore, strongly suggest that the N-terminal domain of ppg, a surface molecule, has the potential of a DNA vaccine candidate to be used in humans.

Acknowledgments

The L. donovani (strain 2039) used in this study was obtained from Prof. Shyan Sundar, Kala Azar Medical Research Centre (Institute of Medical Sciences, Banaras Hindu University, Varanasi). We express our sincere gratitude to the Director of the Central Drug and Research Institute for keen interest and for providing facilities for the experiments. We are also thankful to Aniruddh and Rajesh for technical help. This is Central Drug and Research Institute communication no. 7693.

Disclosures

The authors have no financial conflict of interest.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 This work was supported by the Department of Science and Technology New Delhi and Council for Scientific and Industrial Research Project-Suprainstitutional Network Project No. 0026. M.S., R.G., S.K., P.M., and P.K.K. are the recipients of Council for Scientific and Industrial Research and University Grants Commission fellowships.

  • ↵2 Address correspondence and reprint requests to Dr. Anuradha Dube, Division of Parasitology, Central Drug Research Institute, Post Box 173, Lucknow-226 001, India. E-mail addresses: anuradha_dube{at}hotmail.com or anuradha_dube{at}rediffmail.com

  • ↵3 Abbreviations used in this paper: PG, phosphoglycan; PPG, proteophosphoglycan; VL, visceral leishmaniasis; SLD, soluble Leishmania donovani; iNOS, inducible NO synthase; DTH, delayed-type hypersensitivity; p.c., postchallenge; IPTG, isopropyl-β-d-thiogalactopyranoside; WCL, whole cell lysate; PI, percentage of inhibition; SI, stimulation index; CT, cycle threshold; CMI, cell-mediated immunity; LTT, lymphocyte transformation test.

  • Received January 26, 2009.
  • Accepted April 19, 2009.
  • Copyright © 2009 by The American Association of Immunologists, Inc.

References

  1. ↵
    Foth, B., A. Piani, J. M. Curtis, T. Ilg, M. McConville, E. Handman. 2002. Leishmania major proteophosphoglycans exist as membrane-bound and soluble forms and localise to the cell membrane, the flagellar pocket and the lysosome. Int. J. Parasitol. 32: 1701-1708.
    OpenUrlCrossRefPubMed
  2. ↵
    Mengeling, B. J., D. Zilberstein, S. J. Turco. 1997. Biosynthesis of Leishmania lipophosphoglycan: solubilization and partial characterization of the initiating mannosylphosphoryltransferase. Glycobiology 7: 847-853.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Ilg, T., E. Handman, Y. D. Stierhof. 1999. Proteophosphoglycans from Leishmania promastigotes and amastigotes. Biochem. Soc. Trans. 27: 518-525.
    OpenUrlPubMed
  4. ↵
    Ilg, T., D. Craik, G. Currie, G. Multhaup, A. Bacic. 1998. Stage-specific proteophosphoglycan from Leishmania mexicana amastigotes: structural characterization of novel mono-, di-, and triphosphorylated phosphodiester-linked oligosaccharides. J. Biol. Chem. 273: 13509-13523.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Piani, A., T. Ilg, A. G. Elefanty, J. Curtis, E. Handman. 1999. Leishmania major proteophosphoglycan is expressed by amastigotes and has an immunomodulatory effect on macrophage function. Microbes Infect. 1: 589-599.
    OpenUrlCrossRefPubMed
  6. ↵
    Stierhof, Y. D., M. Wiese, T. Ilg, P. Overath, M. Haner, U. Aebi. 1998. Structure of a filamentous phosphoglycoprotein polymer: the secreted acid phosphatase of Leishmania mexicana. J. Mol. Biol. 282: 137-148.
    OpenUrlCrossRefPubMed
  7. ↵
    Ilg, T., E. Handman, K. Ng, Y. D. Stierhof, A. Bacic. 1999. Mucin-like proteophosphoglycans from the protozoan parasite Leishmania. Trends Glycosci. Glycotechnol. 11: 53-71.
    OpenUrl
  8. ↵
    Ilg, T., Y. D. Stierhof, M. J. McConville, P. Overath. 1995. Purification, partial characterization and immunolocalization of a proteophosphoglycan secreted by Leishmania mexicana amastigotes. Eur. J. Cell Biol. 66: 205-215.
    OpenUrlPubMed
  9. ↵
    Gopfert, U., N. Goehring, C. Klein, T. Ilg. 1999. Proteophosphoglycans of Leishmania mexicana: molecular cloning and characterization of the Leishmania mexicana ppg2 gene encoding the proteophosphoglycans aPPG and pPPG2 that are secreted by amastigotes and promastigotes. Biochem. J. 344: 787-795.
    OpenUrlCrossRefPubMed
  10. ↵
    Klein, C., U. Gopfert, N. Goehring, Y. D. Stierhof, T. Ilg. 1999. Proteophosphoglycans of Leishmania mexicana: identification, purification, structural and ultrastructural characterization of the secreted promastigote proteophosphoglycan pPPG2, a stage-specific glycoisoform of amastigote aPPG. Biochem. J. 344: 775-786.
    OpenUrlCrossRefPubMed
  11. ↵
    Samant, M., A. A. Sahasrabuddhe, N. Singh, S. K. Gupta, S. Sundar, A. Dube. 2007. Proteophosphoglycan is differentially expressed in sodium stibogluconate-sensitive and resistant Indian clinical isolates of Leishmania donovani. Parasitology 134: 1175-1184.
    OpenUrlCrossRefPubMed
  12. ↵
    Turco, S. J., A. Descoteaux. 1992. The lipophosphoglycan of Leishmania parasites. Annu. Rev. Microbiol. 46: 65-94.
    OpenUrlCrossRefPubMed
  13. ↵
    Ng, K., E. Handman, A. Bacic. 1994. Biosynthesis of lipophosphoglycan from Leishmania major: characterization of (β1–3)-galactosyltransferase(s). Glycobiology 4: 845-853.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Ng, K., E. Handman, A. Bacic. 1996. Biosynthesis of lipophosphoglycan from Leishmania major: solubilization and characterization of a (β1–3)-galactosyltransferase. Biochem. J. 317: 247-255.
    OpenUrlPubMed
  15. ↵
    Brown, G. M., A. R. Millar, C. Masterson, J. S. Brimacombe, A. V. Nikolaev, M. A. Ferguson. 1996. Synthetic phospho-oligosaccharide fragments of lipophosphoglycan as acceptors for Leishmania major α-d-mannosylphosphate transferase. Eur. J. Biochem. 242: 410-416.
    OpenUrlPubMed
  16. ↵
    Ma, D., D. G. Russell, S. M. Beverley, S. J. Turco. 1997. Golgi GDP-mannose uptake requires Leishmania LPG2: a member of a eukaryotic family of putative nucleotide-sugar transporters. J. Biol. Chem. 272: 3799-3805.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Ilg, T., J. Montgomery, Y. D. Stierhof, E. Handman. 1999. Molecular cloning and characterization of a novel repeat-containing Leishmania major gene, ppg1, that encodes a membrane-associated form of proteophosphoglycan with a putative glycosylphosphatidylinositol anchor. J. Biol. Chem. 274: 31410-31420.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Montgomery, J., T. Ilg, J. K. Thompson, B. Kobe, E. Handman. 2000. Identification and predicted structure of a leucine-rich repeat motif shared by Leishmania major proteophosphoglycan and parasite surface antigen 2. Mol. Biochem. Parasitol. 107: 289-295.
    OpenUrlCrossRefPubMed
  19. ↵
    Ivens, A. C., C. S. Peacock, E. A. Worthey, L. Murphy, G. Aggarwal, M. Berriman, E. Sisk, M. A. Rajandream, E. Adlem, R. Aert, et al 2005. The genome of the kinetoplastid parasite, Leishmania major. Science 309: 436-442.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Kolaskar, A. S., P. C. Tongaonkar. 1990. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 276: 172-174.
    OpenUrlCrossRefPubMed
  21. ↵
    Carvalho, E. M., R. S. Teixeira, W. D. Johnson, Jr. 1981. Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect. Immun. 33: 498-500.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Carvalho, E. M., R. Badaro, S. G. Reed, T. C. Jones, W. D. Johnson, Jr. 1985. Absence of γ interferon and interleukin 2 production during active visceral leishmaniasis. J. Clin. Invest. 76: 2066-2069.
    OpenUrlCrossRefPubMed
  23. ↵
    Kaye, P. M., A. J. Curry, J. M. Blackwell. 1991. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146: 2763-2770.
    OpenUrlAbstract
  24. ↵
    Kemp, K., M. Kemp, A. Kharazmi, A. Ismail, J. A. Kurtzhals, L. Hviid, T. G. Theander. 1999. Leishmania-specific T cells expressing interferon-γ (IFN-γ) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. Clin. Exp. Immunol. 116: 500-504.
    OpenUrlCrossRefPubMed
  25. ↵
    Kemp, K.. 2000. Cytokine-producing T cell subsets in human leishmaniasis. Arch. Immunol. Ther. Exp. 48: 173-176.
    OpenUrl
  26. ↵
    Kafetzis, D. A., H. C. Maltezou. 2002. Visceral leishmaniasis in paediatrics. Curr. Opin. Infect. Dis. 15: 289-294.
    OpenUrlCrossRefPubMed
  27. ↵
    Murray, H. W.. 2001. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob. Agents Chemother. 45: 2185-2197.
    OpenUrlFREE Full Text
  28. ↵
    Melby, P. C., V. V. Tryon, B. Chandrasekar, G. L. Freeman. 1998. Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infect. Immun. 66: 2135-2142.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Garg, R., J. K. Srivastava, A. Pal, S. Naik, A. Dube. 2005. Isolation of integral membrane proteins of Leishmania promastigotes and evaluation of their prophylactic potential in hamsters against experimental visceral leishmaniasis. Vaccine 23: 1189-1196.
    OpenUrlCrossRefPubMed
  30. ↵
    Garg, R., S. K. Gupta, P. Tripathi, S. Naik, S. Sundar, A. Dube. 2005. Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clin. Exp. Immunol. 140: 149-156.
    OpenUrlCrossRefPubMed
  31. ↵
    Dube, A., P. Sharma, J. K. Srivastava, A. Misra, S. Naik, J. C. Katiyar. 1998. Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitology 116: 219-221.
    OpenUrlCrossRefPubMed
  32. ↵
    Laemmli, U. K.. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
    OpenUrlCrossRefPubMed
  33. ↵
    Towbin, H., T. Staehelin, J. Gordon. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76: 4350-4354.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Tripp, C. A., W. A. Wisdom, P. J. Myler, K. D. Stuart. 1992. A multicopy, extrachromosomal DNA in Leishmania infantum contains two inverted repeats of the 27.5-kilobase LD1 sequence and encodes numerous transcripts. Mol. Biochem. Parasitol. 55: 39-50.
    OpenUrlCrossRefPubMed
  35. ↵
    Myler, P. J., G. M. Venkataraman, M. J. Lodes, K. D. Stuart. 1994. A frequently amplified region in Leishmania contains a gene conserved in prokaryotes and eukaryotes. Gene 148: 187-193.
    OpenUrlCrossRefPubMed
  36. ↵
    Scott, D. A., G. H. Coombs, B. E. Sanderson. 1987. Effects of methotrexate and other antifolates on the growth and dihydrofolate reductase activity of Leishmania promastigotes. Biochem. Pharmacol. 36: 2043-2045.
    OpenUrlCrossRefPubMed
  37. ↵
    Choudhry, A., P. Y. Guru, R. P. Saxena, A. Tandon, K. C. Saxena. 1990. Enzyme-linked immunosorbent assay in the diagnosis of kala-azar in Bhadohi (Varanasi), India. Trans. R. Soc. Trop. Med. Hyg. 84: 363-366.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Bhowmick, S., R. Ravindran, N. Ali. 2007. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. Vaccine 25: 6544-6556.
    OpenUrlCrossRefPubMed
  39. ↵
    Scharton-Kersten, T., P. Scott. 1995. The role of the innate immune response in Th1 cell development following Leishmania major infection. J. Leukocyte Biol. 57: 515-522.
    OpenUrlAbstract
  40. ↵
    Ding, A. H., C. F. Nathan, D. J. Stuehr. 1988. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J. Immunol. 141: 2407-2412.
    OpenUrlAbstract
  41. ↵
    Voller, A., D. E. Bidwell, A. Bartlett. 1979. The Enzyme Linked Immunosorbent Assay (ELISA): A Guide with Abstracts of Microplate Application 1-25. Fileroline Press, Guernsey Ci, U.K..
  42. ↵
    Melby, P. C., B. Chandrasekar, W. Zhao, J. E. Coe. 2001. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J. Immunol. 166: 1912-1920.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Rama Iniguez, S., M. A. Dea-Ayuela, J. A. Sanchez-Brunete, J. J. Torrado, J. M. Alunda, F. Bolas-Fernandez. 2006. Real-time reverse transcription-PCR quantification of cytokine mRNA expression in golden Syrian hamster infected with Leishmania infantum and treated with a new amphotericin B formulation. Antimicrob. Agents Chemother. 50: 1195-1201.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Haldar, J. P., S. Ghose, K. C. Saha, A. C. Ghose. 1983. Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect. Immun. 42: 702-707.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Gifawesen, C., J. P. Farrell. 1989. Comparison of T-cell responses in self-limiting versus progressive visceral Leishmania donovani infections in golden hamsters. Infect. Immun. 57: 3091-3096.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Xu, D., F. Y. Liew. 1994. Genetic vaccination against leishmaniasis. Vaccine 12: 1534-1536.
    OpenUrlCrossRefPubMed
  47. ↵
    Rodríguez-Cortés, A., A. Ojeda, L. López-Fuertes, M. Timón, L. Altet, L. Solano-Gallego, E. Sánchez-Robert, O. Francino, J. Alberola. 2007. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Vaccine 25: 7962-7971.
    OpenUrlCrossRefPubMed
  48. ↵
    Aguilar-Be, I., R. da Silva Zardo, E. Paraguai de Souza, G. P. Borja-Cabrera, M. Rosado-Vallado, M. Mut-Martin, R. Garcia-Miss Mdel, C. B. Palatnik de Sousa, E. Dumonteil. 2005. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect. Immun. 73: 812-819.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    Palatnik-de-Sousa, C. B.. 2008. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 26: 1709-1724.
    OpenUrlCrossRefPubMed
  50. ↵
    Fragaki, K., I. Suffia, B. Ferrua, D. Rousseau, Y. Le Fichoux, J. Kubar. 2001. Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters. Vaccine 19: 1701-1709.
    OpenUrlCrossRefPubMed
  51. ↵
    Melby, P. C., J. Yang, W. Zhao, L. E. Perez, J. Cheng. 2001. Leishmania donovani p36LACK DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69: 4719-4725.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    Sukumaran, B., P. Tewary, S. Saxena, R. Madhubala. 2003. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine 21: 1292-1299.
    OpenUrlCrossRefPubMed
  53. ↵
    Basu, R., S. Bhaumik, J. M. Basu, K. Naskar, T. De, S. Roy. 2005. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J. Immunol. 174: 7160-7171.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    Rafati, S., A. Nakhaee, T. Taheri, Y. Taslimi, H. Darabi, D. Eravani, S. Sanos, P. Kaye, M. Taghikhani, S. Jamshidi, M. A. Rad. 2005. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23: 3716-3725.
    OpenUrlCrossRefPubMed
  55. ↵
    Ramiro, M. J., J. J. Zarate, T. Hanke, D. Rodriguez, J. R. Rodriguez, M. Esteban, J. Lucientes, J. A. Castillo, V. Larraga. 2003. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21: 2474-2484.
    OpenUrlCrossRefPubMed
  56. ↵
    Gonzalo, R. M., G. del Real, J. R. Rodriguez, D. Rodriguez, R. Heljasvaara, P. Lucas, V. Larraga, M. Esteban. 2002. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine 20: 1226-1231.
    OpenUrlCrossRefPubMed
  57. ↵
    Ghosh, A., S. Labrecque, G. Matlashewski. 2001. Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine 19: 3169-3178.
    OpenUrlCrossRefPubMed
  58. ↵
    Ali, N., F. Afrin. 1997. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes. J. Parasitol. 83: 70-75.
    OpenUrlCrossRefPubMed
  59. ↵
    Afrin, F., R. Rajesh, K. Anam, M. Gopinath, S. Pal, N. Ali. 2002. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infect. Immun. 70: 6697-6706.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    Melby, P. C., Y. Z. Yang, J. Cheng, W. Zhao. 1998. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect. Immun. 66: 18-27.
    OpenUrlAbstract/FREE Full Text
  61. ↵
    Armijos, R. X., M. M. Weigel, M. Calvopina, A. Hidalgo, W. Cevallos, J. Correa. 2004. Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine 22: 1320-1326.
    OpenUrlCrossRefPubMed
  62. ↵
    Scott, P., E. Pearce, S. Heath, A. Sher. 1987. Identification of T-cell-reactive antigens that protect BALB/c mice against Leishmania major. Ann. Inst. Pasteur Immunol. 138: 771-774.
    OpenUrlCrossRefPubMed
  63. ↵
    Howard, J. G., F. Y. Liew. 1984. Mechanisms of acquired immunity in leishmaniasis. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 307: 87-98.
    OpenUrlAbstract/FREE Full Text
  64. ↵
    Ghose, A. C., J. P. Haldar, S. C. Pal, B. P. Mishra, K. K. Mishra. 1980. Serological investigations on Indian kala-azar. Clin. Exp. Immunol. 40: 318-326.
    OpenUrlPubMed
  65. ↵
    Kumari, S., M. Samant, P. Khare, P. Misra, S. Dutta, B. K. Kolli, S. Sharma, K. P. Chang, A. Dube. 2009. Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis. Eur. J. Immunol. 39: 178-191.
    OpenUrlCrossRefPubMed
  66. ↵
    Bretscher, P. A., O. Ogunremi, J. N. Menon. 1997. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states. Behring Inst. Mitt. 98: 153-159.
    OpenUrlPubMed
  67. ↵
    Kemp, M., J. A. Kurtzhals, K. Bendtzen, L. K. Poulsen, M. B. Hansen, D. K. Koech, A. Kharazmi, T. G. Theander. 1993. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect. Immun. 61: 1069-1073.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    Liew, F. Y., Y. Li, S. Millott. 1990. Tumor necrosis factor-α synergizes with IFN-γ in mediating killing of Leishmania major through the induction of nitric oxide. J. Immunol. 145: 4306-4310.
    OpenUrlAbstract
  69. ↵
    Liew, F. Y., Y. Li, S. Millott. 1990. Tumour necrosis factor (TNF-α) in leishmaniasis: II. TNF-α-induced macrophage leishmanicidal activity is mediated by nitric oxide from l-arginine. Immunology 71: 556-559.
    OpenUrlPubMed
  70. ↵
    Ghalib, H. W., M. R. Piuvezam, Y. A. Skeiky, M. Siddig, F. A. Hashim, A. M. el-Hassan, D. M. Russo, S. G. Reed. 1993. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J. Clin. Invest. 92: 324-329.
    OpenUrlCrossRefPubMed
  71. ↵
    Noben-Trauth, N., R. Lira, H. Nagase, W. E. Paul, D. L. Sacks. 2003. The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J. Immunol. 170: 5152-5158.
    OpenUrlAbstract/FREE Full Text
  72. ↵
    Karp, C. L., S. H. el-Safi, T. A. Wynn, M. M. Satti, A. M. Kordofani, F. A. Hashim, M. Hag-Ali, F. A. Neva, T. B. Nutman, D. L. Sacks. 1993. In vivo cytokine profiles in patients with kala-azar: marked elevation of both interleukin-10 and interferon-γ. J. Clin. Invest. 91: 1644-1648.
    OpenUrlCrossRefPubMed
  73. ↵
    Murray, H. W., C. Montelibano, R. Peterson, J. P. Sypek. 2000. Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis. J. Infect. Dis. 182: 1497-1502.
    OpenUrlAbstract/FREE Full Text
  74. ↵
    Rodrigues Junior, V., J. S. Da Silva, A. Campos-Neto. 1992. Selective inability of spleen antigen presenting cells from Leishmania donovani infected hamsters to mediate specific T cell proliferation to parasite antigens. Parasite Immunol. 14: 49-58.
    OpenUrlCrossRefPubMed
  75. ↵
    Montgomery, J., J. Curtis, E. Handman. 2002. Genetic and structural heterogeneity of proteophosphoglycans in Leishmania. Mol. Biochem. Parasitol. 121: 75-85.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Immunology: 183 (1)
The Journal of Immunology
Vol. 183, Issue 1
1 Jul 2009
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Immunization with the DNA-Encoding N-Terminal Domain of Proteophosphoglycan of Leishmania donovani Generates Th1-Type Immunoprotective Response against Experimental Visceral Leishmaniasis
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Immunization with the DNA-Encoding N-Terminal Domain of Proteophosphoglycan of Leishmania donovani Generates Th1-Type Immunoprotective Response against Experimental Visceral Leishmaniasis
Mukesh Samant, Reema Gupta, Shraddha Kumari, Pragya Misra, Prashant Khare, Pramod Kumar Kushawaha, Amogh Anant Sahasrabuddhe, Anuradha Dube
The Journal of Immunology July 1, 2009, 183 (1) 470-479; DOI: 10.4049/jimmunol.0900265

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Immunization with the DNA-Encoding N-Terminal Domain of Proteophosphoglycan of Leishmania donovani Generates Th1-Type Immunoprotective Response against Experimental Visceral Leishmaniasis
Mukesh Samant, Reema Gupta, Shraddha Kumari, Pragya Misra, Prashant Khare, Pramod Kumar Kushawaha, Amogh Anant Sahasrabuddhe, Anuradha Dube
The Journal of Immunology July 1, 2009, 183 (1) 470-479; DOI: 10.4049/jimmunol.0900265
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Early Self-Regulatory Mechanisms Control the Magnitude of CD8+ T Cell Responses Against Liver Stages of Murine Malaria
  • Sublethal Hyperoxia Impairs Pulmonary Innate Immunity
  • Dependence of IL-4, IL-13, and Nematode-Induced Alterations in Murine Small Intestinal Smooth Muscle Contractility on Stat6 and Enteric Nerves
Show more HOST DEFENSE

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606